Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470208 | 0.89 | FGFR2 (0.40) | PRKD1TGFBR1EGFRKDRFLT1 | |
| SCHEMBL3469529 | 0.87 | PRKD1 (0.41) | PRKD1TGFBR1EGFRKDRFLT1 | |
| SCHEMBL3470512 | 0.85 | SYK (0.49) | PRKD1EGFRFGFR2FLT3SYK | |
| SCHEMBL3469679 | 0.83 | PRKD1 (0.40) | PRKD1TGFBR1EGFRKDRFLT1 | |
| SCHEMBL3470478 | 0.81 | MAPKAPK5 (0.43) | PRKD1TGFBR1EGFRKDRFLT1 | |
| SCHEMBL11939505 | 0.80 | FLT1 (0.47) | PRKD1EGFRKDRFLT1FGFR2 | |
| SCHEMBL14537044 | 0.77 | AURKA (0.45) | PRKD1EGFRFLT1FGFR2FLT3 | |
| SCHEMBL3468104 | 0.77 | FGFR2 (0.42) | PRKD1EGFRFLT1FGFR2FLT3 | |
| SCHEMBL8241606 | 0.77 | AURKA (0.58) | EGFRFGFR2FLT3SYKMAPKAPK5 | |
| SCHEMBL3471097 | 0.77 | PIP4K2A (0.44) | SYKMAPKAPK5CYP1A2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010069684-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-06-24 | — | — | WO | claimed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2364702-A2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | Emory University (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010069684-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069684-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-06-24 | — | — | WO | disclosed |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | PRKD1 280/4885TGFBR1 2840/4885EGFR 711/4885 |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | ABL1, LCK, SRC | PRKD1 523/4885TGFBR1 2817/4885EGFR 119/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | PRKD1 280/4885TGFBR1 2840/4885EGFR 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.